An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs

Deepak Bhattarai, Sarbijt Singh, Yerin Jang, Seung Hyeon Han, Kyeong Lee, Yongseok Choi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Increased investments and development of new technologies in drug discovery have barely improved the outcome of medicinal entities in the drug discovery market from a long time. Minimal success rates of drug approvals, poor safety profiles, and long development processes are some of many hurdles encountered in the drug discovery field. Therefore, drug repurposing can provide an alternative approach to meet the demands of the new, potent and safe anti-cancer agents in terms of both economic cost and time efficiency. The common molecular pathways of different diseases and secondary indications of most of the approved drugs, and advances in genomics, informatics and biology, as well as the availability of approved or safe drug libraries can certainly provide an improved and efficient way of screening safer drugs for new indications. Promising results of drug repurposing in different therapeutic areas have encouraged the scientific community to discover new drugs for different diseases using this methodology. Herein, we provide a general overview of structurally and functionally diverse approved drugs that have been repurposed as anti-cancer drugs.

Original languageEnglish
Pages (from-to)2156-2168
Number of pages13
JournalCurrent Topics in Medicinal Chemistry
Volume16
Issue number19
Publication statusPublished - 2016 Aug 1

Fingerprint

Drug Repositioning
Drug Discovery
Pharmaceutical Preparations
Neoplasms
Drug Approval
Preclinical Drug Evaluations
Informatics
Genomics
Economics
Technology
Safety
Costs and Cost Analysis

Keywords

  • Anti-cancer
  • Approved drugs
  • Drug discovery
  • Repurposing
  • Safety
  • Secondary indication

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Bhattarai, D., Singh, S., Jang, Y., Han, S. H., Lee, K., & Choi, Y. (2016). An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs. Current Topics in Medicinal Chemistry, 16(19), 2156-2168.

An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs. / Bhattarai, Deepak; Singh, Sarbijt; Jang, Yerin; Han, Seung Hyeon; Lee, Kyeong; Choi, Yongseok.

In: Current Topics in Medicinal Chemistry, Vol. 16, No. 19, 01.08.2016, p. 2156-2168.

Research output: Contribution to journalArticle

Bhattarai, D, Singh, S, Jang, Y, Han, SH, Lee, K & Choi, Y 2016, 'An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs', Current Topics in Medicinal Chemistry, vol. 16, no. 19, pp. 2156-2168.
Bhattarai, Deepak ; Singh, Sarbijt ; Jang, Yerin ; Han, Seung Hyeon ; Lee, Kyeong ; Choi, Yongseok. / An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs. In: Current Topics in Medicinal Chemistry. 2016 ; Vol. 16, No. 19. pp. 2156-2168.
@article{009966a2725445e4a255cc2d0394cee0,
title = "An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs",
abstract = "Increased investments and development of new technologies in drug discovery have barely improved the outcome of medicinal entities in the drug discovery market from a long time. Minimal success rates of drug approvals, poor safety profiles, and long development processes are some of many hurdles encountered in the drug discovery field. Therefore, drug repurposing can provide an alternative approach to meet the demands of the new, potent and safe anti-cancer agents in terms of both economic cost and time efficiency. The common molecular pathways of different diseases and secondary indications of most of the approved drugs, and advances in genomics, informatics and biology, as well as the availability of approved or safe drug libraries can certainly provide an improved and efficient way of screening safer drugs for new indications. Promising results of drug repurposing in different therapeutic areas have encouraged the scientific community to discover new drugs for different diseases using this methodology. Herein, we provide a general overview of structurally and functionally diverse approved drugs that have been repurposed as anti-cancer drugs.",
keywords = "Anti-cancer, Approved drugs, Drug discovery, Repurposing, Safety, Secondary indication",
author = "Deepak Bhattarai and Sarbijt Singh and Yerin Jang and Han, {Seung Hyeon} and Kyeong Lee and Yongseok Choi",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "16",
pages = "2156--2168",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "19",

}

TY - JOUR

T1 - An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs

AU - Bhattarai, Deepak

AU - Singh, Sarbijt

AU - Jang, Yerin

AU - Han, Seung Hyeon

AU - Lee, Kyeong

AU - Choi, Yongseok

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Increased investments and development of new technologies in drug discovery have barely improved the outcome of medicinal entities in the drug discovery market from a long time. Minimal success rates of drug approvals, poor safety profiles, and long development processes are some of many hurdles encountered in the drug discovery field. Therefore, drug repurposing can provide an alternative approach to meet the demands of the new, potent and safe anti-cancer agents in terms of both economic cost and time efficiency. The common molecular pathways of different diseases and secondary indications of most of the approved drugs, and advances in genomics, informatics and biology, as well as the availability of approved or safe drug libraries can certainly provide an improved and efficient way of screening safer drugs for new indications. Promising results of drug repurposing in different therapeutic areas have encouraged the scientific community to discover new drugs for different diseases using this methodology. Herein, we provide a general overview of structurally and functionally diverse approved drugs that have been repurposed as anti-cancer drugs.

AB - Increased investments and development of new technologies in drug discovery have barely improved the outcome of medicinal entities in the drug discovery market from a long time. Minimal success rates of drug approvals, poor safety profiles, and long development processes are some of many hurdles encountered in the drug discovery field. Therefore, drug repurposing can provide an alternative approach to meet the demands of the new, potent and safe anti-cancer agents in terms of both economic cost and time efficiency. The common molecular pathways of different diseases and secondary indications of most of the approved drugs, and advances in genomics, informatics and biology, as well as the availability of approved or safe drug libraries can certainly provide an improved and efficient way of screening safer drugs for new indications. Promising results of drug repurposing in different therapeutic areas have encouraged the scientific community to discover new drugs for different diseases using this methodology. Herein, we provide a general overview of structurally and functionally diverse approved drugs that have been repurposed as anti-cancer drugs.

KW - Anti-cancer

KW - Approved drugs

KW - Drug discovery

KW - Repurposing

KW - Safety

KW - Secondary indication

UR - http://www.scopus.com/inward/record.url?scp=84975761204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975761204&partnerID=8YFLogxK

M3 - Article

C2 - 26881715

AN - SCOPUS:84975761204

VL - 16

SP - 2156

EP - 2168

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 19

ER -